[EN] HEXACYCLIC POLYKETIDES AS KINASE INHIBITORS<br/>[FR] POLYCÉTIDES HEXACYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
申请人:INST BIOMAR SA
公开号:WO2012010606A1
公开(公告)日:2012-01-26
Compounds of general formula (I) wherein the R1, R2, R3 and R4 groups are each independently selected from the group consisting of hydrogen, acyl, alkyl, alkenyl, alkynyl, aryl, aralkyl, -CONH2, alkali metal, and sugar and X1, X2 groups are each independently selected from the group consisting of hydrogen and halogen, or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof, a method of producing them, and their use for the treatment of cancer, Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, peripheral neuropathies, brain, spinal cord trauma, atherosclerosis, balloon injury induced restenosis, pulmonary fibrosis, and liver fibrosis, graft versus host disease (GvHD), transplant rejection, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, asthma, psoriasis, human multiple myeloma, T cell acute lymphoblastic leukemia and Hodgkin's disease, as protein kinase inhibitors.